Sector News

Novo Nordisk to invest 100 mln euros in Chartres production site

April 21, 2016

Danish insulin maker Novo Nordisk said on Thursday it planned to invest 100 million euros in production facilities at its existing 32,000 square metres site in Chartres, France.

Novo Nordisk already employs 1,400 people in France, where a range of the company’s insulin products are produced and exported from.

“With the coming expansion we will further strengthen Chartres’ position in our global product supply organisation,” said Chief Executive Officer, Lars Rebien Sørensen in a statement.

By Nikolaj Skydsgaard

Source: Reuters

comments closed

Related News

August 23, 2019

The higher purpose of being a CEO

Borderless Leadership

LinkedIn Twitter Xing EmailWhen I left my second large company experience to become President of a small manufacturing company I did so driven by ego; I fancied the title. Soon […]

August 23, 2019

As Brexit nears, Britain’s drugs, devices and pricing regulators seek the exit

Life sciences

LinkedIn Twitter Xing EmailFirm details on exactly how the U.K. will regulate new medicines is still to be decided after it leaves the EU later this year (caveats on timing […]

August 23, 2019

The Simply Good Foods Company acquires Quest Nutrition for $1bn

Consumer Packaged Goods

LinkedIn Twitter Xing EmailThe Simply Good Foods Company, the owner of Atkins-branded food products, has secured a deal to acquire protein snack maker Quest Nutrition for $1 billion. Quest, which […]

How can we help you?

We're easy to reach